Patients | 90-day mortality | P-value | Total mortality | Risk ratio* | P-value | |||
LVRS | Medical therapy | LVRS | Medical therapy | |||||
Group A | 20/70 (28.6) | 0/70 (0) | <0.001 | 42/70 | 30/70 | 1.82 | 0.06 | |
Group B | 4/139 (2.9) | 5/151 (3.3) | 1.00 | 26/139 | 51/151 | 0.47 | 0.005 | |
Group C | 6/206 (2.9) | 2/213 (0.9) | 0.17 | 34/206 | 39/213 | 0.98 | 0.7 | |
Group D | 7/84 (8.3) | 0/65 (0) | 0.02 | 28/84 | 26/65 | 0.81 | 0.49 | |
Group E | 11/109 (10.1) | 1/111 (0.9) | 0.003 | 27/109 | 14/111 | 2.06 | 0.02 | |
Patients | Improvement in exercise capacity¶ | Improvement in health-related quality of lifeΔ | ||||||
LVRS | Medical therapy | Odds ratio | P-value | LVRS | Medical therapy | Odds ratio | P-value | |
Group A | 4/58 (7) | 1/48 (2) | 3.48 | 0.37 | 6/58 (10) | 0/48 (0) | --- | 0.03 |
Group B | 25/84 (30) | 0/92 (0) | --- | <0.001 | 40/84 (48) | 9/92 (10) | 8.38 | <0.001 |
Group C | 17/115 (15) | 4/138 (3) | 5.81 | 0.001 | 47/115 (41) | 15/138 (11) | 5.67 | <0.001 |
Group D | 6/49 (12) | 3/41 (7) | 1.77 | 0.5 | 18/49 (37) | 3/41 (7) | 7.35 | 0.001 |
Group E | 2/65 (3) | 2/59 (3) | 0.9 | 1 | 10/65 (15) | 7/59 (12) | 1.35 | 0.61 |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟